Munich Re analyzed the effectiveness of daily sleep duration in stratifying the mortality risk profile of a U.S. insured population simulated from National Center for Health Statistics survey data.
An increase in opioid misuse has contributed to a rise in overdose mortality, gaining the attention of the media, Hollywood, and legislators.
Is the recent slowdown of mortality improvement observed amongst the U.S. population also happening in the individual life insurance population, and what are the implications for the future?
When one looks at a curve of the mortality rates by age in developed countries, we notice a very regular pattern. Especially the middle-age groups - age 30 to 70+, for example - seem to have close to an exponential curve in mortality rates.
Are cannabis, hemp and marijuana the same thing? What are THC and CBD? Are the medicinal benefits of cannabis true? What are the health risks? And as of now, is there enough data to assess the mortality impact?
considered by life insurance underwriters are highly influenced by routine clinical assessments, often undertaken in acute situations following an episode of self-directed violence.
Life insurers have long recognized the value of oral fluids for risk assessment through screening for HIV-1 and tobacco or drug use, but oral health itself is not routinely evaluated as part of the underwriting process.
Rapid medical advances, as well as growing volumes of health and mortality data, are transforming cancer risk assessment. RGA's Neil Parkin explores our deepening understanding and insurance implications.
One of the toughest situations for an underwriter is the case that seems to have literally fallen off the cliff. A condition that is significant, that is being followed, and that does have mortality consequences suddenly has no notes of any recency for six months or more. Follow-up that appeared to be favorable virtually disappears, and the underwriter is left with guessing that things have continued to go reasonably well. Or not...
Munich Re assessed the Milliman Rx Risk Score, a predictive modeling tool developed and owned by Milliman that assesses mortality risk using an individual’s prescription drug information. Insurers considering prescription- drug-based scores should begin with a retrospective validation study on their own experience data.